; or (B) $20,000 for each day of a continuing violation; and (2) an amount equal to the retail value of the human cell and tissue products that are the subject of the violation. (b) Maximum penalty The total civil penalty under subsection (a) shall not exceed $10,000,000 for all such violations adjudicated in a single proceeding. 5. Report to Congress Not later than 2 years after the date of enactment of this Act, the Secretary shall submit to Congress a report that describes actions Congress and the Food and Drug Administration could take to improve the safety of human cell and tissue products, including— (1) an examination of existing regulations and guidance relating to human cell and tissue products; (2) documentation of the number of human cell and tissue establishments that have registered with the Food and Drug Administration since 1998; (3) how often the Food and Drug Administration has inspected human cell and tissue establishments since 1998, including a comparison of the inspection rates for blood establishments and Source Plasma establishments with the inspection rates for such human cell and tissue establishments, potential causes of declines in such inspections, if applicable, and recommendations to increase Food and Drug Administration resources, if applicable; and (4) recommendations on potential guidance or regulations that could be issued or promulgated, as applicable, to improve donor screening for human cell and tissue products. 6. Review and update of existing guidance The Secretary, acting through the Commissioner of Food and Drugs, shall— (1) not later than 1 year after the date of enactment of this Act, initiate an internal review of existing guidance for determining eligibility of donors of human cell and tissue products